Sodium-dependent Glucose Transporters 2 Inhibitor in Nonobstructive Hypertrophic Cardiomyoapthy Patients With Heart Failure With Preserved Ejection Fraction: a Prospective, Multi-center,Open-lable,Randomized Controlled Trial
Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 4
SUMMARY
This study aims to evaluate the impact of Sodium-dependent glucose transporters 2 inhibitor Empagliflozin on the exercise capacity,symptoms of heart failure, cardiac function, myocardial remodeling and quality of life of nonobstructive HCM patients with HFpEF.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:
• Patients with a diagnosis of nonobstructive hypertrophic cardiomyopathy;
• At least 18 years old;
• LVEF≥50%
• Elevated NT-proBNP \>300 pg/ml for patients without atrial fibrillation (AF), or \>900 pg/ml for patients with AF at Visit 1;
• NYHA II-IV
• Capable of performing cardiopulmonary exercise test with an RER≥1.0
• Signed and dated written informed consent and willing to return for clinical follow-up.
Locations
Other Locations
China
Fuwai Hospital, National Centre for Cardiovascular Disease, Chinese Academy of Medical Sciences and Peking Union Medical College
RECRUITING
Beijing
Time Frame
Start Date: 2022-08-01
Estimated Completion Date: 2025-08-01
Participants
Target number of participants: 94
Treatments
Experimental: Study group
Use of Empagliflozin+guideline directed medical treatment of HCM
No_intervention: Control group
Guideline directed medical treatment of HCM
Related Therapeutic Areas
Sponsors
Leads: China National Center for Cardiovascular Diseases